MetaCap

TransCode Therapeutics (RNAZ) vs TherapeuticsMD (TXMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TherapeuticsMD (TXMD) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 3.9% versus a loss of 86.6%. Over five years, TXMD leads with a -94.1% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($20.1 million vs $19.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RNAZ-86.57%TXMD-3.93%
+63%-15%-94%
Nov 21, 20251 yearNov 20, 2026
RNAZ-100.00%TXMD-94.00%
+17%-45%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RNAZ versus TXMD key metrics
MetricRNAZTXMD
Share price$1.16$1.71
Market cap$20.07M$19.79M
1-day change-10.77%-5.52%
YTD return-83.02%+4.91%
1-year return-86.57%-3.93%
5-year return-100.00%-94.10%
P/E ratio (TTM)—171.00
Forward P/E—4.89
EPS (TTM)$-47.95$0.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.02M
Revenue growth (YoY)—+71.61%
Net income (latest FY)$-34.66M$-569.00K
Operating margin—-145.27%
Net margin—-18.83%
52-week high$12.60$2.95
52-week low$1.01$1.43
Distance from 52-week high-90.79%-42.03%
Average volume52.03K24.50K
Shares outstanding17.30M11.57M
Employees121
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TXMD has outperformed RNAZ by 82.6 percentage points over the past year.

About TransCode Therapeutics

RNAZ stock →

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About TherapeuticsMD

TXMD stock →

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

RNAZ vs TXMD FAQ

Which is bigger, TransCode Therapeutics or TherapeuticsMD?

TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $20.07M compared with $19.79M for TherapeuticsMD (TXMD).

Which stock has performed better over the past year, RNAZ or TXMD?

TXMD returned -3.93% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.

Are TransCode Therapeutics and TherapeuticsMD in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons